Groupama Asset Managment Purchases 1,305 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Groupama Asset Managment increased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 19.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,099 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,305 shares during the period. Groupama Asset Managment’s holdings in Jazz Pharmaceuticals were worth $996,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of JAZZ. Trexquant Investment LP lifted its position in shares of Jazz Pharmaceuticals by 25.7% in the fourth quarter. Trexquant Investment LP now owns 49,297 shares of the specialty pharmaceutical company’s stock valued at $6,071,000 after acquiring an additional 10,090 shares in the last quarter. HighPoint Advisor Group LLC grew its holdings in Jazz Pharmaceuticals by 21.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,556 shares of the specialty pharmaceutical company’s stock valued at $332,000 after buying an additional 456 shares in the last quarter. O Shaughnessy Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $5,519,000. Allianz SE purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $29,000. Finally, Cornercap Investment Counsel Inc. purchased a new position in Jazz Pharmaceuticals during the fourth quarter valued at $518,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the sale, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. This represents a 10.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 1,140 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the transaction, the chief accounting officer now owns 7,012 shares in the company, valued at approximately $966,323.72. This represents a 13.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,236 shares of company stock worth $3,837,680 in the last 90 days. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Up 1.2 %

NASDAQ:JAZZ opened at $126.44 on Thursday. The company has a market cap of $7.68 billion, a price-to-earnings ratio of 17.81, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a fifty day simple moving average of $132.54 and a 200-day simple moving average of $122.92.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on JAZZ shares. JPMorgan Chase & Co. lifted their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Royal Bank of Canada lowered their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. Piper Sandler reiterated an “overweight” rating and set a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Morgan Stanley restated an “overweight” rating and set a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Buy” and an average price target of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.